Lupin zooms on receiving USFDA`s approval for Selexipag for Injection
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Lupin is currently trading at Rs. 1177.45, up by 44.90 points or 3.96% from its previous closing of Rs. 1132.55 on the BSE.
The scrip opened at Rs. 1139.90 and has touched a high and low of Rs. 1183.85 and Rs. 1135.00 respectively. So far 211055 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1215.20 on 17-Oct-2023 and a 52 week low of Rs. 628.10 on 31-Mar-2023.
Last one week high and low of the scrip stood at Rs. 1183.85 and Rs. 1113.00 respectively. The current market cap of the company is Rs. 53402.00 crore.
The promoters holding in the company stood at 47.06%, while Institutions and Non-Institutions held 44.42% and 8.52% respectively.
Lupin has received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application for Selexipag for Injection, 1800 mcg/vial, Single-Dose Vial, to market a generic equivalent of Uptravi for Injection, 1800 mcg/vial, of Actelion Pharmaceuticals US, Inc. This product will be manufactured at Lupin’s Nagpur facility in India.
The product sales for Selexipag Franchise (RLD Uptravi) in U.S. were $1,104 million for the year ended December 2022 and $978 million for the fiscal nine months ended October 1, 2023.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
